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Abstract Mammaglobin-A (MAM-A) is a secretory
protein that is overexpressed in 80 % of human breast
cancers. Its near-universal expression in breast cancer as
well as its exquisite tissue specificity makes it an attractive
target for a breast cancer prevention vaccine, and we
recently initiated a phase 1 clinical trial of a MAM-A DNA
vaccine. Previously, we have identified multiple MAM-A
CD8 T cell epitopes using a reverse immunology candidate
epitope approach based on predicted binding, but to date no
attempt has been made to identify epitopes using an
unbiased approach. In this study, we used human T cells
primed in vitro with autologous dendritic cells expressing
MAM-A to systematically identify MAM-A CD8 T cell
epitopes. Using this unbiased approach, we identified three
novel HLA-A2-restricted MAM-A epitopes. CD8 T cells
specific for these epitopes are able to recognize and lyse
human breast cancer cells in a MAM-A-specific, HLA-A2-
dependent fashion. HLA-A2?/MAM-A? breast cancer
patients have an increased prevalence of CD8 T cells
specific for these novel MAM-A epitopes, and vaccination
with a MAM-A DNA vaccine significantly increases the
number of these CD8 T cells. The identification and
translational validation of novel MAM-A epitopes has
important implications for the ongoing clinical develop-
ment of vaccine strategies targeting MAM-A. The novel
MAM-A epitopes represent attractive targets for epitope-
based vaccination strategies, and can also be used to
monitor immune responses. Taken together these studies
provide additional support for MAM-A as an important
therapeutic target for the prevention and treatment of breast
cancer.
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Introduction
Cancer vaccination has broad appeal because of the potential
for selective tumor destruction, minimal systemic toxicity,
and sustained benefit secondary to immunologic memory.
Preclinical studies and human clinical trials have demon-
strated that CD8 T cells are key effectors in mediating
antitumor immunity. The choice of antigen to be targeted by
cancer vaccination is critical, since the antigen can influence
not only the efficacy of the antitumor immune response, but
also the potential for autoimmunity [30].
Mammaglobin-A (MAM-A) is a 10 kD secretory pro-
tein that was first identified by Watson and Fleming using a
differential screening approach [39]. In normal tissues,
MAM-A expression is restricted almost exclusively to
normal breast epithelium, where it is expressed at low
levels [15]. MAM-A is overexpressed in 80 % of human
breast cancers, and expression is observed in all stages of
disease (ductal carcinoma in situ, invasive breast cancer,
and metastatic disease) [9, 38]. The consistent and dramatic
expression of MAM-A in breast cancer, as well as its
exquisite tissue specificity makes it an attractive target for
breast cancer vaccine therapy. In proof-of-concept studies,
we demonstrated the safety and potential efficacy of a
MAM-A DNA vaccine in a preclinical model [2, 25].
Based on these studies, we recently initiated a phase 1
clinical trial of a MAM-A DNA vaccine in breast cancer
patients with metastatic disease [34].
CD8 T cells recognize antigen as peptide fragments
presented at the cell surface by HLA class I molecules.
While we have previously identified MAM-A-derived
epitopes restricted by HLA-A2 and other class I alleles [2,
17, 18, 23, 32, 36, 37], and validated the translational
relevance of these epitopes in breast cancer patients [15,
17, 18, 35], these epitopes were identified through a reverse
immunology candidate epitope approach [19]. This means
that candidate epitopes were initially identified based on
predicted binding using a computer algorithm. The candi-
date epitopes were then validated by peptide binding assays
in vitro, by generating CD8 T cell lines in vitro, and by
determining the frequency of epitope-specific CD8 T cells
in MAM-A? breast cancer patients.
In the present study we used an unbiased approach to
systematically identify potential MAM-A-derived CD8 T
cell epitopes. We generated MAM-A-specific T cells
in vitro by priming naı¨ve T cells with autologous dendritic
cells transduced to express MAM-A. With this unbiased
approach, MAM-A-derived epitopes are naturally pro-
cessed, presented, and recognized by functional T cell
repertoires. The same techniques have been used success-
fully to identify novel RVFV epitopes [40]. We identified
three novel HLA-A2-restricted MAM-A epitopes. Of note,
some of the most robust responses observed in the initial
cultures were directed at these epitopes, and CD8 T cells
specific for these epitopes were able to recognize and lyse
breast cancer cells in a MAM-A-specific, HLA-A2-
dependent manner. In addition, we show that CD8 T cell
immunity to these epitopes can be enhanced by vaccination
with a MAM-A DNA vaccine in the context of a phase 1
clinical trial. These studies highlight the advantages of an
unbiased approach to epitope identification and confirm the
potential of MAM-A as a breast cancer antigen.
Materials and methods
Study subjects
Healthy donor PBMC specimens were obtained from
human platelet apheresis specimens. The specimens were
isolated by density gradient centrifugation and stored in
liquid nitrogen until evaluation. Peripheral blood was
obtained from breast cancer patients after informed consent
in accordance with a protocol approved by the Institutional
Review Board at Washington University School of Medi-
cine (WUSM).
Peptides
A library of 21 overlapping peptides (P1–P21) spanning the
entire MAM-A protein was synthesized. Each MAM-A
peptide was 15 amino acids in length, and peptides over-
lapped by 4 amino acids. The MAM-A peptide library and
a Flu-M1 control peptide [13] were synthesized by Bio-
synthesis (Lewisville, TX). A pool of 23 viral-derived
peptides (including known HLA class I-restricted T cell
epitopes from cytomegalovirus, Epstein-Barr virus, and
influenza virus, [6] ) was obtained from CTL Technologies
(Shaker Heights, OH).
In vitro generation of MAM-A-specific CD8 T cells
For initial studies, PBMC from two healthy donors were
used to generate monocyte-derived dendritic cells, as
described [40]. Dendritic cells from each donor were
transduced with a lentiviral vector expressing full length
MAM-A and co-cultured at a dendritic cell to T cell ratio
of 1:10 with autologous CD8 T cells (2 9 106/mL) purified
by magnetic bead separation (Miltenyi Biotec; Auburn,
CA). T cells were cultured in RPMI-1640 medium, sup-
plemented with 5 % human AB serum (Sigma; St. Louis,
MO) in 24-well plates. 50 U/mL recombinant IL-2 was
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added to the cultures after 24 h, and then every 48 h. T
cells were restimulated after 7–9 days using autologous,
irradiated monocytes pulsed with the peptide library. In
subsequent cultures, total PBMC were cultured in the
presence of 20 lg of an individual peptide. PBMC stimu-
lated with the immunodominant peptide (GILVFTFTL) of
the influenza matrix protein (Flu-M1) were included as
positive control.
Breast cancer cell lines
All breast cancer cell lines were obtained from the Amer-
ican Type Culture Collection (Manassas, VA). Breast
cancer cell lines were cultured in RPMI-1640 medium
(Gibco; Grand Island, NY) supplemented with 10 % fetal
bovine serum, 1 % L-glutamine, and 1 % penicillin/strep-
tomycin at 37 C in a 5 % CO2 incubator.
ELISPOT assay
PBMC and CD8 T cell cultures were tested using an IFNc-
based enzyme-linked ImmunoSpot (ELISPOT) assay kit
(Mabtech; Stockholm, Sweden). Briefly, 96-well filtration
plates (Millipore; Darmstadt, Germany) were pre-coated
with 12 lg/mL of the anti-IFNc monoclonal antibody
1-DIK (Mabtech; Nacka Strand, Sweden) and kept at 4 C
until use. A total of 1.25 9 105 or 6.25 9 105 PBMC or T
cells as well as 5 9 104 antigen-presenting cells (APC),
HeLa or T2 cells, were then plated in duplicate in 100 lL
of culture medium (RPMI-1640, 5 % fetal bovine serum,
1 % L-glutamine, 1 % penicillin/streptomycin) per well,
plus peptide at a final concentration of 40 lg/mL. For
blocking studies, stimulator cells were pulsed with peptide
for 1 h and subsequently incubated with the anti-MHC
class I mAb W6/32 (Bio Legend; San Diego, CA) or the
anti-HLA-A2 mAb BB7.2 (Abcam; Cambridge, UK) for
30 min. Additional antibody (1 lg) was added to each well.
Mouse Ig (BD Bioscience) was used as a negative control.
Cells were cultured for 20 h at 37 C in a humidified 5 %
CO2 atmosphere. Plates were then washed with phosphate
buffered saline (PBS), and 100 lL of PBS containing 1 lg/
mL of biotinylated anti-IFNc monoclonal antibody, 7-B6-
1-biotin (Mabtech) was added to each well. After 2 h,
plates were washed and horseradish peroxidase streptavidin
(Mabtech) was added at a dilution of 1:1,000 in PBS for
1 h. Spots were revealed by incubation with BCIP/NBT
substrate for 3 min. The spots were then counted with a
Cellular Technology Limited (CTL) ELISPOT analyzer.
The average number of spots per well was used to express
each experimental value as spot-forming cells (SFCs) per
106 PBMC or T cells. All assays included positive (Flu-M1,
CEF) and negative (PBMC/T cells alone and stimulator
cells without peptide) controls.
Flow cytometry based killing assay (FloKa)
A flow-based killing assay [14] was used to measure in vitro
cellular cytotoxicity of CD8? T cells. Breast cancer cell lines
(AU-565 and MCF-7) were washed with PBS, re-suspended
at 1 9 107 cells/mL, and then labeled at room temperature
for 15 min with 125 nM final concentration of 5- (and 6-)
carboxyfluorescein diacetate succinimidyl ester (CFSE;
Invitrogen; Carlsbad, CA). Labeling reactions were stopped
with complete RPMI media. Labeled target cells (2.5 9 104)
were added to 96-well V-bottom tissue culture-treated plates
along with T cells in complete RPMI media containing 50 U/
mL of rhIL-2 and incubated at 37 C for 4 h. The effector-
target (E/T) ratio was 40:1 for all time points shown.
Immediately before analysis, 5 lL of 7-aminoactinomycin
D (7-AAD) (Calbiochem; La Jolla, CA) was added to each
sample. 7-AAD incorporation is associated with cell death/
apoptosis, as it intercalates with DNA in cells that have lost
membrane integrity. The samples were then analyzed by
flow cytometry on a FACScalibur flow cytometer (BD
Biosciences; San Jose, CA) and CFSE?7-AAD? tumor cells
were counted. The acquired data were analyzed with Flowjo
software. All cytotoxicity assays were performed in dupli-
cate or triplicate. Data presented are representative of four
individual cytotoxicity experiments.
Peptide-binding assay
To determine whether the epitopes identified can bind to
HLA-A2, a MHC stabilization assay was performed using
T2 cells that are deficient in presentation of endogenous
peptides, as described previously [4, 7, 25, 31, 33]. T2 cells
(1 9 106/well) were incubated with different concentra-
tions of individual peptide in 24-well plates for 18 h at
25 C. A melanoma-associated epitope (G280-9 V) was
used as a positive control [21]. The cells were washed with
FACS buffer (1 % BSA and 0.1 % sodium azide in PBS)
and stained with a FITC-conjugated mAb specific for
HLA-A2 (BB7.2, BD Biosciences) at 4 C for 30 min.
After incubation, the cells were washed with FACS buffer,
fixed with 1 % paraformaldehyde in PBS, and analyzed by
flow cytometry using a FACSCalibur device (BD Biosci-
ences) and mean fluorescence intensity (MFI) was recor-
ded. The acquired data was analyzed with Flowjo software.
The percent MFI increase was calculated as follows: per-
cent MFI increase = (MFI with the given peptide-MFI
without peptide)/(MFI without peptide) 9 100.
Phase 1 clinical trial of a MAM-A DNA vaccine
We initiated a phase 1 clinical trial of a MAM-A DNA
vaccine at WUSM to evaluate the safety and immunoge-
nicity of a plasmid MAM-A DNA vaccine [34]. Fourteen
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HLA-A2? and/or HLA-A3? patients with metastatic breast
cancer were treated with the MAM-A DNA vaccine.
Patients had stable disease for at least 30 days after che-
motherapy, or for at least 30 days on hormonal therapy.
The vaccine was administered intramuscularly using the
Biojector 2000 Needle-Free Injection Management System
on days 0, 28, and 56. Peripheral blood specimens were
obtained before and after vaccination as indicated. PBMC
were isolated from heparinized blood by density gradient
centrifugation using Ficoll-Hypaque and stored in liquid
nitrogen until evaluation.
Results
Unbiased identification of novel MAM-A candidate T
cell epitopes
We used autologous DC transduced with a lentiviral vector
to express MAM-A to identify MAM-A-derived CD8 T
cell epitopes. Circulating CD8 T cells from two healthy
HLA-A2-positive donors were primed and expanded by
autologous DC prepared as noted above. The ability of the
stimulated CD8 T cells to produce cytokines in response to
each individual MAM-A peptide, or a pool of all peptides,
was then determined by IFNc ELISPOT and flow cytom-
etry analysis (intracellular cytokine staining) (Fig. 1).
Representative ELISPOT and intracellular cytokine data
are shown in Fig. 1a, b, and show IFNc production in
response to P2, P12, P13, and the peptide pool. Cytokine
production was not limited to IFNc, as IL-2 and TNFa
were detectable as well. In addition to cytokine production,
CD107a/b, a surrogate marker for cytolytic activity, was
upregulated after peptide stimulation. Of note, both donors
responded to P2, P12, and P13, whereas one of two donors
responded to P5, P16, P20, and P21 (data not shown). As
HLA-A2 CD8 T cell epitopes have previously been iden-
tified in P16, P20, and P21 [18, 32], they were not char-
acterized further.
Generation of CD8 T cell lines specific for candidate
MAM-A-derived peptides
CD8 T cell lines specific for the P2, P5, P12, and P13
peptides were established using PBMC from both HLA-
A2-positive healthy donors and breast cancer patients. In
initial studies CD8 T cell lines were established from two
additional healthy donors, and the activity and specificity
was assessed by IFNc ELISPOT. CD8 T cell lines showed
specific recognition for the peptide used for stimulation
when presented by peptide-pulsed HeLa or T2 cells, but not
for irrelevant HLA-A2-binding peptides (p \ 0.05, Fig. 1c,
d). Unstimulated PBMC typically did not yield sufficient
cells for testing, whereas PBMC stimulated with Flu-M1
peptide typically induced [500 SFU/106 cells for the Flu-
M1 peptide but not the MAM-A-derived peptides (data not
shown). CD8 T cell lines specific for the P2, P5, P12, and
P13 peptides were also generated from patients with breast
cancer. These cultures also showed peptide specificity by
ELISPOT (Supplementary Fig. 1a, b). In cultures from
some individuals we observed the response to P5 was lower
than the response to P2 and/or P12. Recognition of peptides
was restricted by HLA-A2, as evidenced by the ability of
an anti-HLA-A2 mAb, and/or an anti-HLA class I mAb to
significantly block IFNc release by T cells (p \ 0.05,
Fig. 1e). In contrast, a mouse Ig control antibody had no
effect on IFNc release.
Identification of minimal peptide epitopes
The minimal epitopes corresponding to P2, P5, P12, and
P13 were predicted using the NetMHC 3.2 prediction
algorithm [22] (Fig. 2). The minimal epitopes for the P12
and P13 peptides are identical. Binding of synthetic
peptides encoding these minimal epitopes to HLA-A2 was
confirmed using T2 cells (Fig. 2). The CD8 T cell
response observed to each of the minimal epitopes was
comparable to the response observed to the corresponding
parent peptides, confirming that the minimal epitopes
identified by the prediction algorithms are likely the
native epitopes.
The novel MAM-A epitopes are processed
and presented by breast cancer cells
To assess whether the MAM-A epitopes are naturally
processed and presented by breast cancer cells, we deter-
mined if the CD8 T cell lines specific for P2, P5, and P12/
13 could recognize breast cancer cells. The ability of two
human breast cancer cell lines, AU565 (MAM-A?, HLA-
A2?) and MCF-7 (MAM-A-, HLA-A2?), to be recognized
by MAM-A-specific CD8 T cell lines from four breast
cancer patients was tested by ELISPOT. The CD8 T cell
lines were able to recognize the MAM-A? AU565 breast
cancer cells, but not the MAM-A- MCF-7 breast cancer
cells (Fig. 3a). Addition of anti-HLA class I mAb or anti-
HLA-A2 mAb significantly impaired recognition of
AU565 breast cancer cells, confirming that recognition of
the MAM-A? tumor cells is HLA-A2 restricted (Fig. 3a).
Of note, CD8 T cells were able to recognize MCF-7 cells
pulsed with either the P2 or P12 peptides, but not an
irrelevant peptide, demonstrating that MCF-7 cells can
present antigen effectively (Supplementary Fig. 2). Rec-
ognition of MCF-7 cells pulsed with MAM-A peptides was
almost completely abrogated by anti-HLA-A2 mAb (Sup-
plementary Fig. 2b).
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To determine whether IFNc secretion as measured by
ELISPOT was associated with cytolytic activity, we
assessed the ability of CD8 T cell lines to lyse human
breast cancer cell lines using a flow-based killing assay
(FloKA). CD8 T cell lines were able to lyse the MAM-A?
AU565 breast cancer cell line (40–60 % specific lysis), but
not the MAM-A- MCF-7 breast cancer cell line (\15 %
specific lysis) (Fig. 3b, c). A control CD8 T cell line
developed against Flu-M1 was able to lyse Flu-M1 peptide-
pulsed HeLa cells ([90 % specific lysis) but showed
minimal lysis of the two breast cancer cell lines (\10 %
specific lysis). Thus, CD8 T cells specific for the novel
MAM-A-derived epitopes specifically lyse breast cancer
cells in an HLA-restricted fashion, indicating that these
epitopes are naturally processed and presented by breast
cancer cells.
Detection of pre-existing immunity against MAM-A-
derived epitopes in breast cancer patients
To assess whether the novel MAM-A-derived epitopes are
associated with pre-existing CD8 T cell responses, we
obtained PBMC from breast cancer patients. PBMC from
six HLA-A2? breast cancer patients (3 with MAM-A?
Fig. 1 Identification of novel CD8 T cell epitopes encoded by MAM-
A. a Naı¨ve CD8 T cells from two HLA-A2? healthy individuals were
stimulated with autologous dendritic cells modified to express MAM-
A. Primed T cells were tested for MAM-A reactivity using APC
pulsed with a pool of 21 overlapping peptides (P1–P21) of 15 amino
acids each, staggered by four residues across the MAM-A protein.
IFNc ELISPOT results from Donor 1 are displayed and show
responses to P2, P12, P13, and a pool of all 21 peptides. Flow
cytometry analysis shows degranulation (increased surface CD107a/b
expression), and production of IFNc, IL-2, and TNFa triggered by P2
or the peptide pool after a 6 h stimulation of CD8 T cells with
peptide-pulsed C1R-A2 target cells. The numbers in the upper right
quadrants indicate the percentage of dual positive cells. Gates were
set using T cells cocultured with target cells in the absence of peptide
(not shown) b Intracellular cytokine analysis of MAM-A-stimulated
CD8 T cells from healthy donor 2 analyzed as above c, d Naı¨ve
PBMC from two additional HLA-A2? healthy individuals were
cultured with MAM-A-derived peptides to generate epitope-specific
CD8 T cell cultures. After in vitro culture, epitope specificity was
assessed by IFNc ELISPOT assay. ELISPOT data from two
representative healthy individuals are shown. e CD8 T cell cultures
specific for MAM-A epitopes are HLA-A2-specific. Epitope-specific
CD8 T cells were tested for recognition of epitope-pulsed APC in the
presence or absence of antibodies specific for HLA class I or HLA-
A2. Error bars represent standard error, *p \ 0.05
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breast cancers, and 3 with MAM-A- breast cancers) were
analyzed by ELISPOT in ex vivo analyses. Of note, spe-
cific activity against the MAM-A-derived epitopes was
observed in the three patients with MAM-A? breast can-
cers, but little or no activity was observed in the three
patients with MAM-A- breast cancers (Fig. 4). The
response to P5 was consistently lower than the response to
P2, P12, or P13. Reactivity against a pool of viral-derived
peptides (CEF peptide) was observed among all six
patients (data not shown).
MAM-A DNA vaccination enhances the CD8 T cell
response to the novel MAM-A-derived epitopes
To assess the translational relevance of the MAM-A epi-
topes, we measured the immune response to these epitopes
before and after vaccination with a MAM-A DNA vaccine.
PBMC samples were collected from breast cancer patients
enrolled in a phase 1 clinical trial of a MAM-A DNA
vaccine. As shown in Fig. 5, four out of five HLA-A2?
patients tested had markedly increased IFNc responses
specific for the novel epitopes following vaccination. The
IFNc responses against the P2, P5, and P12 peptides were
similar to the responses to the minimal epitopes (data not
shown). These results support the translational relevance of
these epitopes for immune monitoring and/or epitope-spe-
cific vaccination strategies.
Discussion
MAM-A is a breast cancer-associated antigen that is an
attractive target for cancer vaccine therapy. We have pre-
viously identified epitopes derived from MAM-A using a
reverse immunology candidate epitope approach [12, 17,
18, 23, 32, 36, 37]. In this study we used an unbiased
approach to identify three novel HLA-A2-restricted CD8 T
cell epitopes derived from MAM-A. We confirmed the
significance of these epitopes demonstrating that (1) the
novel MAM-A epitopes are naturally processed and pre-
sented by human breast cancers; (2) MAM-A? breast
cancer patients have a pre-existing CD8 T cell response to
these epitopes; and (3) vaccination with a MAM-A DNA
vaccine can enhance this pre-existing immune response.
Epitope identification is an important focus of human
immunology research. Most studies have used a reverse
immunology candidate epitope approach to identify epi-
topes. In this study we used an unbiased approach to
identify MAM-A epitopes. We first developed and opti-
mized this approach for the identification of epitopes
within targeted regions of the HIV proteome [28]. Using
combinatorial peptide libraries, we were able to success-
fully identify and validate novel HIV epitopes, even though
the immunobiology of HIV has been studied extensively.
These HIV epitopes are naturally processed and presented
by HIV-infected cells, and recognized by precursor T cell
repertoires in healthy donors and HIV-infected patients
[29]. The ability to identify and validate epitopes derived
from well-studied viral and shared tumor antigens under-
scores the translational relevance of this unbiased epitope
identification strategy.
There are many potential factors that contribute to
whether a candidate epitope is immunologically significant
(immunodominant). The reverse immunology candidate
epitope approach focuses on predicted binding as the key
first step in prioritizing potential epitopes for further study.
Although the reverse immunology approach has been used
successfully, there are a number of potential limitations
with this approach. First, predicted binding is highly
dependent on sequences of known epitopes. For many
Fig. 2 Identification of candidate minimal MAM-A epitopes. Left
panel The epitope prediction algorithm, Net-MHC3.2 (http://www.
cbs.dtu.dk/services/NetMHC-3.2/) was used to define candidate
minimal epitopes of P2 and P12/13 with the highest predicted binding
to HLA-A2. Right panel The candidate minimal peptides were
synthesized and tested for binding to HLA-A2 using T2 cells, as
described [7, 33]. Binding of predicted minimal epitopes from both
P2 and P12/13 was detected as an intensity similar to the reference
mammaglobin-A peptide, MamA2.1 [18]
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HLA alleles, predicted binding is based on limited infor-
mation, and predicted binding may not identify all immu-
nologically significant epitopes. Second, for an epitope to
be immunologically significant, the T cell repertoire must
be capable of recognizing the epitope. This is particularly
important for candidate epitopes derived from shared
tumor antigens. As shared tumor antigens are self-antigens,
the T cell repertoire may be shaped/limited by central and
Fig. 3 CD8 T cells specific for novel MAM-A epitopes recognize
and lyse breast cancer cells. a HLA-A2?, MAM-A? breast cancer
cells (AU565), but not HLA-A2?, MAM-A- breast cancer cells
(MCF-7) are recognized by peptide-specific CD8 T cells. PBMC from
breast cancer patients (n = 5) were stimulated with P2, P5, and P12,
and tested for recognition of breast cancer cells. Representative data
show recognition of AU565 breast cancer cells was HLA-A2
restricted, as demonstrated by specific blocking with anti-HLA-A2
and anti-class I HLA antibodies, but not anti-mouse Ig control
antibody (control Ig). Insert shows representative ELISPOT images of
P12-stimulated T cells (1.25 9 105 T cells/well) b PBMC from breast
cancer patients were stimulated with P2 or P12 and the ability to lyse
MAM-A expressing breast cancer cells was assessed by FloKA.
Representative flow cytometry analysis of T cell-mediated killing of
the HLA-A2?/MAM-A? breast cancer cell line AU565 is shown. c
Lysis of CFSE-labeled breast cancer cells was determined using
7-AAD staining. The bar graph shows percent specific lysis of breast
cancer cells (AU565, MCF-7) by epitope-specific T cells. Lysis of
Flu-M1-pulsed APC by Flu-M1-specific T cells serves as a control.
Error bars represent standard error, *p \ 0.05
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peripheral tolerance mechanisms. The unbiased approach
to epitope identification addresses many of the potential
limitations of the reverse immunology approach. Of note,
all of the novel MAM-A epitopes identified in this study
appear to be translationally significant, confirming the
relevance of the unbiased approach.
Identification of novel MAM-A epitopes has significant
translational implications. Translational applications
include integration into epitope-based vaccination strate-
gies, and immune monitoring. We are currently testing a
MAM-A DNA vaccine in phase 1 clinical trials. This
nucleic acid-based approach is not epitope-specific as the
whole antigen is expressed and can be targeted by the
immune system. However, several current cancer vaccine
platforms are epitope-specific including the synthetic pep-
tide vaccine platform [41] and selected dendritic cell vac-
cine platforms [27]. The synthetic peptide vaccine platform
is perhaps the most common cancer vaccine platform given
the remarkable safety and ease of manufacture of synthetic
peptides. The development and translational success of
synthetic long peptide vaccines has further increased the
interest in the synthetic vaccine platform. The epitopes
identified in this study are attractive candidates for inte-
gration into a synthetic peptide vaccine targeting MAM-A.
Immune monitoring is critical to assessing the efficacy
of cancer vaccines. Although measurement of clinical
outcomes such as overall and progression-free survival
remains the benchmark for assessing efficacy of any ther-
apeutic intervention particularly in late phase clinical trials,
immune monitoring is a valuable surrogate for biologic
efficacy, particularly in early phase clinical trials. Current
immune monitoring techniques are epitope-based, includ-
ing ELISPOT and multi-parameter flow cytometry. The
MAM-A epitopes identified here represent attractive can-
didates for immune monitoring. CD8 T cell responses to
these epitopes were particularly robust in vitro, suggesting
that the epitopes are effectively processed. In addition, the
response to these epitopes was consistent across multiple
individuals, suggesting that the T cell repertoires to these
epitopes remain intact. These observations suggest that the
novel epitopes may be ideal for immune monitoring.
Of note, breast cancer patients with MAM-A? breast
cancer have pre-existing CD8 T cell responses to the novel
Fig. 4 Patients with MAM-A-expressing tumors have pre-existing
immunity to the novel MAM-A epitopes. Pre-existing immunity to
MAM-A epitopes in breast cancer patients was assessed directly
ex vivo by IFNc ELISPOT using 15-mer peptides. The results
represent results from four patients with MAM-A? breast can-
cers (dots), and four patients with MAM-A- breast cancers (trian-
gles). The number of IFNc SFU/106 PBMC in the absence of peptide
was \15 (not shown)
Fig. 5 MAM-A cDNA vaccination significantly enhances T cell
responses to the novel MAM-A-derived peptides in breast cancer
patients. Breast cancer patients were vaccinated three times with a
MAM-A DNA vaccine in the context of a phase 1 clinical trial. The
immune response to MAM-A epitopes was assessed before and after
vaccination by IFNc ELISPOT. The immune response (IFNc SFU/
106 PBMC) was significantly enhanced following vaccination in four
of five patients evaluated. Symbols indicate individual patients
534 Breast Cancer Res Treat (2014) 147:527–537
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MAM-A epitopes. These studies confirm and extend the
results of Bharat et al., who demonstrated pre-existing CD8
T cell responses to the MAM-A2.1 epitope in breast cancer
patients by tetramer and ELISPOT analysis [2]. Pre-exist-
ing CD8 T cell responses to shared tumor antigens have
been previously described in melanoma patients [3, 11, 20,
26], and for the shared tumor antigens HER2 [8] and NY-
ESO-1 [16]. Immunohistochemistry studies in breast and
other solid malignancies [1] now suggest that endogenous
antitumor CD8 T cell responses are associated with a
favorable prognosis [3]. However, despite an improved
prognosis, many patients with endogenous antitumor CD8
T cell responses ultimately progress [3], suggesting that the
endogenous antitumor CD8 T cell response may ultimately
become ineffective, either because of antigen loss, loss of
class I HLA expression, or because of functional inacti-
vation of tumor-specific CD8 T cells [3]. Functional
inactivation of CD8 T cells is commonly associated with
expression of programmed death-1 (PD-1) [10], and we
recently demonstrated that PD-1 expression by breast
cancer tumor infiltrating lymphocytes (TIL) is associated
with larger primary tumor size, higher tumor grade, posi-
tive lymph node status, and an unfavorable prognosis [24].
Demonstration of pre-existing CD8 T cell responses to the
novel MAM-A epitopes identified in this study confirms
their translational significance.
A second confirmation of the relevance of the novel
MAM-A epitopes is the demonstration that vaccination
with a MAM-A DNA vaccine can significantly increase the
pre-existing CD8 T cell response to these epitopes. As
noted above, MAM-A is an attractive candidate for a breast
cancer prevention vaccine. As the first step in the clinical
translation of a MAM-A DNA vaccine, we recently initi-
ated a phase 1 clinical trial in breast cancer patients with
metastatic disease. Of note, MAM-A DNA vaccination
significantly enhances the pre-existing immune response to
the novel MAM-A CD8 T cell epitopes at 6 months fol-
lowing vaccination as measured by ELISPOT. This con-
firms and extends the study by Tiriveedhi et al. based on
the same phase 1 clinical trial demonstrating that MAM-A
DNA vaccination is able to successfully induce MAM-A-
specific CD4 T cells following vaccination [34]. These
results are also consistent with ELISPOT and tetramer
analyses that we have performed based on previously
identified MAM-A epitopes demonstrating a response to
vaccination. A detailed analysis of the primary endpoints of
the phase 1 clinical trial, including safety of the vaccine,
clinical response, ELISPOT analyses, and peptide-MHC
tetramer analyses documenting the safety and immunoge-
nicity of the MAM-A cDNA vaccine is currently under
review (Tiriveedhi et al., manuscript submitted).
We have successfully identified the minimal epitopes for
each of the overlapping peptides in the present study. The
identification of the minimal epitopes is important as the
minimal epitopes represent what is actually presented by
HLA-A2 molecules and recognized by CD8 T cells. This
information is required for epitope-based vaccination
strategies and immune monitoring. Identification of the
minimal epitopes also provides the opportunity to engineer
the epitopes to improve the immunogenicity of epitope-
based vaccination strategies. For instance, epitopes can be
modified to improve binding to HLA-A2, or to improve
interaction with the TCR of responding T cells. In addition,
identification and translational validation of multiple CD8
T cell epitopes provides the opportunity to combine these
epitopes into a multi-epitope vaccine. Recent studies in
preclinical models have shown that DNA vaccination with
constructs containing multiple epitopes results in the
induction of strong CD8 and CD4 T cell responses to all of
the epitopes in the vaccines [5]. The results reported have
the potential to influence epitope selection, and are likely to
influence the future design of epitope-based MAM-A
vaccines and strategies for immune monitoring.
In summary, we present a novel and broadly applicable
approach to the identification of novel MAM-A CD8 T cell
epitopes. CD8 T cells specific for these epitopes are able to
specifically recognize and lyse human breast cancer cells in
a MAM-A-specific, HLA-A2-dependent fashion. Patients
with MAM-A? breast cancer have evidence of a preexist-
ing CD8 T cell immune response specific to these epitopes,
and this preexisting immune response is increased fol-
lowing vaccination with MAM-A DNA vaccine. These
results support the use of an unbiased approach for the
identification of novel epitopes from shared tumor anti-
gens, and support our strategy to target MAM-A for breast
cancer prevention and therapy.
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